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Epigenetic regulation of the Hedgehog-Gli signaling
pathway in cancer
The term epigenetics refers to the modulation of gene expression
caused by means other than changes in the DNA sequence.
Alongside with genetic alterations, epigenetic changes can also be
considered a hallmark of cancer. Epigenetic silencing of tumor sup-
pressors can serve as one of the hits in the Knudson’s two hit model of
tumor initiation when in conjunction with genetic mutations or dele-
tions. Also, loss of methylation can be implicated in tumorigenesis by
activating normally silent regions of the genome.
The Hedgehog-Gli (Hh-Gli) signaling pathway has been highly
conserved through evolution and plays a crucial role during embryonic
development from Drosophila to humans.
Malfunction of the Hh-Gli signaling pathway in humans has first
been observed in Gorlin syndrome, characterized by developmental
malformations and cancer susceptibility. In the last decades aberrant
activation of the Hh-Gli signaling pathway has been implicated in vari-
ous sporadic tumors, both benign and malignant ones.
Genetic alterations of the Hh-Gli signaling pathway components
and their implication in the development of various types of cancer and
developmental malformations are well known. In the last few years it
has become obvious that epigenetic changes also play a crucial role in
the regulation of this pathway.
EPIGENETIC GENE REGULATION IN CANCER
The term epigenetics refers to the modulation of gene expression
caused by means other than changes in the DNA sequence. These
modulations play a crucial role in development and differentiation, but
they can also occur in adult tissues, by random change or under the in-
fluence of environment (1).
Epigenetic mechanisms that modify the chromatin structure can be
divided into four categories: DNA methylation, covalent histone modi-
fications, non-covalent modifications and non-coding RNAs including
microRNAs. In normal cells these modifications act together to regu-
late gene expression patterns in different cell types or different develop-
mental stages (2).
Alongside with genetic alterations, changes in DNA methylation
can also be considered a hallmark of cancer. DNA methylation is a co-
valent modification of the postreplicative DNA where DNA methyl-
transferases add a methyl group to the cytosine ring and form 5-methyl
cytosine. In mammals, this modification is predominant in cytosines of
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the CpG dinucleotide sequence. CpG dinucleotides are
more common in certain regions of the genome and form
so called CpG islands. These islands are frequently lo-
cated at the 5’ end of genes and occupy about 60% of hu-
man gene promoters. Most of the CpG sites in the ge-
nome are methylated, but the majority of the CpG islands
remain unmethylated during development and in differ-
entiated tissues (2). However, some CpG islands can be-
come methylated during development, which results in
long term gene silencing. It has been reported that such
events occur during the development of some tumors,
where the promoters of tumor suppressor genes become
hypermethylated (3). Epigenetic silencing of tumor sup-
pressors can serve as one of the hits in the Knudson’s two
hit model of tumor initiation when in conjunction with
genetic mutations or deletions (Figure 1) (2).Also, loss of
methylation can be implicated in tumorigenesis by acti-
vation of normally silent regions of the genome. These
regions can contain silenced genes, inserted viral genes
or repeat elements which are potentially harmful when
expressed abnormally. Loss of methylation in regions
other than genes can affect chromosomal stability in can-
cer (3). Such an event can activate oncogenes and initiate
tumor formation.
HEDGEHOG-GLI SIGNALING PATHWAY
The Hh-Gli signaling pathway (Figure 2) has been
highly conserved through evolution and played a crucial
role during embryonic development from Drosophila to
humans. It has been first discovered in the fruit fly, when
Nüsslein-Volhard and Wieschaus (5) identified muta-
tions in the Hedgehog gene that caused a short and
spiked phenotype of the Drosophila larvae, similar to
hedgehog spikes. Despite the fact that the key compo-
nents of the signaling pathway are conserved, this path-
way in mammals has some alterations compared to the
fruit fly (6).
In humans, there are three different homologues of
the pathway ligand Hedgehog: Sonic Hedgehog (Shh),
Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh),
which are all tissue specific. Prior to activation and secre-
tion from the producing cell, the Hh protein is subjected
to autocatalytic cleavage, as well as dual lipid modifica-
tions at the N- and C- termini (7). Any of these forms of
the Hh protein can bind to the receptor Patched (Ptch), a
12-pass transmembrane protein that represses another
transmembrane protein, Smoothened (Smo), in the in-
active state. There are two human homologues of the
PTCH gene, PTCH1 and PTCH2, whereas there is
only one human homologue of Smoothened (SMOH).
After ligand binding, Ptch relieves its repression of Smo,
allowing activation of downstream signaling through the
Suppressor of Fused (SuFu), which, in turn, leads to the
activation and nuclear translocation of the zinc finger
transcription factor Gli (8). In the absence of Hh signal,
SuFu acts as a negative regulator of the signaling path-
way because it inhibits Gli-mediated transcription by re-
cruiting a histone deacetylation complex to Gli target
genes. SuFu also sequesters Gli to the cytoplasm (9). Ver-
tebrates have three isoforms of the Gli transcription fac-
tor, Gli1, Gli2 and Gli3 (10). Among direct Gli1 trans-
criptional targets are PTCH1 and GLI1, representing a
negative and positive feedback loop, respectively (11).
Malfunction of the Hh-Gli signaling pathway in hu-
mans has first been observed in Gorlin syndrome, a med-
ical condition characterized by developmental malfor-
mations as well as susceptibility to various tumors. The
syndrome is caused by a germline mutation in the PTCH
gene. PTCH haploinsufficiency is the cause of anoma-
lies, whereas a somatic mutation of the second PTCH al-
lele leads to tumor formation (8).
In the last decades aberrant activation of the Hh-Gli
signaling pathway has been implicated in various spo-
radic tumors, both benign and malignant ones. There
are many known genetic alterations associated to the
components of this signaling pathway that cause its aber-
rant activation in adult tissues. Once aberrantly activated
it promotes tumor formation and progression by upregu-
lating the transcription of direct target genes. These tar-
gets include regulators of cell cycle progression (D-type
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Figure 1. Knudson’s two hit model. Two hits are necessary to inactivate tumor suppressor genes and lead to cancer development. Promoter
hypermethylation can represent the first or the second hit and lead to tumorigenesis in conjunction with point mutations or loss of heterozygosity by
deletions of the functional allele.
cyclins), proliferation (myc proto-oncogene) and metas-
tasis (Snail, a transcription factor that is associated with
increased invasiveness and metastasis). Also, the Gli tran-
scription factors can promote cell survival by upregula-
ting the anti-apoptotic protein Bcl2 (4).
Tumors usually associated with Gorlin syndrome, such
as basocellular carcinoma, medulloblastoma, rhabdomyo-
sarcoma, fibramas of the heart and ovary, meningioma
and odontogenic cysts, have been associated with chan-
ges in the Hh-Gli signaling pathway as sporadic cases
(12–15). Apart from these tumors, there is growing evi-
dence of Hh-Gli pathway involvement in many other le-
thal tumors: melanoma (16, 17), trichoepithelioma (18),
rhabdomyoma and rhabdomyosarcoma (19, 20), diges-
tive tract tumors (21), prostate (22), small cell lung can-
cer (23), squamous lung cancer (24), pancreatic cancer
(25), bladder cancer (26, 27), pituitary adenoma (28),
breast cancer (29), ovarian cancer (30, 31) and chronic
myeloid leukemia (32).
EPIGENETIC REGULATION OF THE
MEMBERS OF THE HEDGEHOG-GLI
SIGNALING PATHWAY
Genetic alterations of the Hh-Gli signaling pathway
components and their implication in the development of
various types of cancer and developmental malforma-
tions are well known. In the last few years it has become
obvious that epigenetic changes are as crucial in the reg-
ulation of this pathway as the genetic ones. Promoter
hypermethylation has mostly been reported in the tumor
suppressor PTCH and has been implicated in the devel-
opment of various cancers. In 2007, our laboratory re-
ported higher methylation of the PTCH1 promoter re-
gion in ovarian dermoids and fibromas, compared to
normal ovarian tissue. In several cases the expression of
GLI1 was elevated, but Ptch did not seem to be conse-
quently activated in either of them. The analysis showed
that tumors were mostly methylated in the CpG island
located in the PTCH1 promoter region near the Gli bind-
ing sites, whereas normal tissues showed no methylation
at those sites. We suggested that hypermethylation of the
Gli-binding site on the PTCH promoter contributes to
tumor growth in ovarian fibroma and dermoids because
it obstructs the pathway negative feedback loop in which
GLI1 stimulates the expression of PTCH. In the cases
where there was no elevation in the expression of GLI,
tumor proliferation most likely did not rely on Gli activ-
ity. On the other hand, there was no change observed in
the PTCH promoter methylation status in basal cell car-
cinomas, compared to healthy skin (33).
The PTCH promoter was also found to be methyl-
ated in the ER positive, well differentiated breast cancer
cell line MCF-7 as well as breast cancer samples. Methy-
lation was identified in the promoter that regulates the
transcription of the exon 1b, which encodes the N-termi-
nal part of the fully active Ptch protein. These samples
showed low Ptch expression, which was also validated by
immunohistochemistry using an antibody specific for
this N-terminal region. This suggests that the downre-
gulation of the active form of Ptch by promoter hyper-
methylation may be associated with the Hh pathway ac-
tivation (34).
Du et al. analyzed the promoter methylation status of
the PTCH1a transcript in a gastric cancer cell line AGS,
as well as in gastric cancer tissues. Their results indicated
that the transcriptional regulation region of PTCH1a
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Figure 2. Illustration of theHedgehog signaling pathway. (A) In the absence of Hh ligand, Ptch represses Smo and consequently the pathway is inac-
tive. SuFu tethersGli to the cytoplasm and inhibits Gli-mediated transcription by recruiting a histone deacetylase complex toGli target genes (4). (B)
In the presence of Hh ligand, Hh binds to Ptch, which relieves its repression of Smo and activates the pathway that leads to target gene expression.
Hedgehog-interacting protein (Hhip) also binds Hh and regulates ligand availability.
was hypermethylated in the AGS cell line. After treat-
ment with 5-Aza-dC, almost all sites became unmethy-
lated, which was followed by an upregulation of PTCH1
expression and induction of apoptosis. They also found
hypermethylation of the PTCH1 promoter in 32% of
gastric cancer tissues, compared to no methylation in ad-
jacent normal tissue. This methylation correlated nega-
tively with the PTCH1 gene expression and was not re-
lated to clinical features of gastric cancer. This suggested
that hypermethylation of the PTCH1a transcriptional
regulating region is an early event in gastric carcinoge-
nesis (35).
Another negative regulator of the Hh-Gli signaling
pathway that has been shown to be downregulated in
various cancer types by promoter hypermethylation is
the Hh-interacting protein (HHIP). Hhip is a mem-
brane-bound protein that can bind all human Hh pro-
teins with an affinity similar to that of Ptch1. Thereby it
regulates the availability of ligand and attenuates signal-
ing (36). Tada et al. showed that HHIP promoter methy-
lation reduced HHIP mRNA transcription in a subset of
hepatoma and hepatoblastoma cell lines. Also, this pro-
moter was hypermethylated in more than 50% of HCC
tissues, but no methylation was detected in the corre-
sponding healthy tissues. This led to downregulation of
HHIP transcription, and consequently to elevated tran-
scription of GLI1 and PTCH, suggesting that the down-
regulation of HHIP leads to the Hh signal activation in
HCC. Treating the hepatoma cell lines with a demethyl-
ating agent restored HHIP expression and attenuated
Hh signaling. Thus, signal activation through the inacti-
vation of HHIP may be implicated in the tumorigenesis
of HCC (37).
HHIP promoter hypermethylation was also observed
in a subset of pancreatic cancer cell lines and pancreatic
cancer tissue samples. Epigenetic reactivation of HHIP
expression reduced hedgehog pathway activity (37).
In their investigation of the Hh signaling pathway ac-
tivation in medulloblastoma, glioblastoma and neuro-
blastoma, Shahi et al. found higher expression of GLI1
and lower expression of PTCH1 in a subset of medullo-
blastoma and glioblastoma cell lines. After the treatment
of these cell lines with demethylating agents, PTCH1 ex-
pression increased, which would support its promoter
methylation as a means of activating the Hh signal.
They also demonstrated the methylation of the pro-
moter of SMO, an activator of the Hh signaling pathway,
in cell lines and tumors despite a normal level of SMO
expression in these cell lines and samples. They observed
an increase in SMO expression after treatment with de-
methylating agents but, nevertheless, they suggest that
methylation does not play a significant role in SMO si-
lencing (39). Wang et al. investigated the expression of
SHH and altered methylation of its promoter in gastric
cancer and its related lesions. The level of SHH expres-
sion was significantly higher in advanced gastric cancer
than in the early stages. Analysis of the promoter methy-
lation status revealed partial methylation in only one of
63 carcinoma samples, and no methylation in other le-
sions. However, promoter methylation was frequent in
normal gastric pit. They suggested that SHH is the link
between chronic tissue injury and cancer and that pro-
moter (de) methylation is the major regulatory mecha-
nism of expression (40).
All these results have shown classic examples of epi-
genetic deregulation in tumorigenesis, such as tumor
suppressor inactivation by promoter hypermethylation
(PTCH and HHIP) and oncogene activation caused by
promoter demethylation in tumors. This indicates the
importance of epigenetic regulation of the Hh-Gli sig-
naling components. Therefore, investigations in this field
need to be deepened in order to fully understand the
mechanisms of epigenetic regulation of this pathway and
its potential as a therapeutic target. It would also be inter-
esting to see whether SUFU, another negative regulator
of the pathway, undergoes such regulation, which may
also be an important step in tumorigenesis. Furthermore,
other mechanisms of epigenetic regulation of this path-
way have not been investigated to the same extent as pro-
moter methylation, so this is something for future inves-
tigations to focus on.
REFERENCES
1. JAENISCH R, BIRD A 2003 Epigenetic regulation of gene expres-
sion: how the genome integrates intrinsic and environmental sig-
nals. Nat Genet 33: 245–54
2. SHARMA S, KELLY T K, JONES P A 2010 Epigenetics in cancer.
Carcinogenesis 31(1): 27–36
3. HERMAN J G 1999 Hypermethylation of tumor suppressor genes
in cancer. Semin Cancer Biol 9(5): 359–67
4. KASPER M, REGL G, FRISCHAUF A M, ABERGER F 2006 GLI
transcription factors: mediators of oncogenic Hedgehog signalling.
Eur J Cancer 42(4): 437–45
5. NUSSLEIN-VOLHARD C, WIESCHAUS E 1980 Mutations af-
fecting segment number and polarity in Drosophila. Nature 287:
795–801
6. VARJOSALO M, TAIPALE J 2008 Hedgehog: functions and mech-
anisms. Genes Dev 22(18): 2454–72
7. LUM L, BEACHY P A 2004 The Hedgehog response network: sen-
sors, switches, and routers. Science 304(5678): 1755–9
8. LEVANAT S, CRETNIK M, MUSANI V 2008 Hh-Gli signaling
pathway functions and its therapeutic potential in cancer. Croat
Chem Acta 81(1): 1–5
9. JIA J, KOLTERUD A, ZENG H, HOOVER A, TEGLUND S,
TOFTGÅRD R, LIU A 2009 Suppressor of Fused inhibits mamma-
lian Hedgehog signaling in the absence of cilia. Dev Biol 330(2):
452–60
10. PAN Y, BAI C B, JOYNER A L, WANG B 2006 Sonic hedgehog sig-
naling regulates Gli2 transcriptional activity by suppressing it pro-
cessing and degradation. Mol Cell Biol 26(9): 3365–3377
11. KATOH Y, KATOH M 2006 Hedgehog signaling pathway and gas-
trointestinal stem cell signaling network (review). Int J Mol Med
18(6): 1019–23
12. LEVANAT S, MUSANI M, KOMAR A, ORE[KOVI] S 2004 Role
of the Hedgehog/Patched signaling pathway in oncogenesis. Ann N
Y Acad Sci. 1030: 134–143
13. BOOTH D R 1999 The hedgehog signaling pathway and its role in
basal cell carcinoma. Cancer Metast Reviews 18: 261–284
14. PIETSCH T, WAHA A, KOCH A, KRAUS J, ALBRECHT S,
TONN J, SÖRENSEN N, BERTHOLD F, HENK B, SCH-
MANDT N, OLF H K, VON DEIMLING A, WAINWRIGHT B,
CHEVENIX-TRENCH G, WIESTLER O D, WICKING C 1997
Medulloblastomas of the desmoplastic variant carry mutations of the
human homologue of Drosophila patched.CancerRes 57: 2085–2088
422 Period biol, Vol 112, No 4, 2010.
Diana Car et al. Epigenetic regulation of the Hedgehog signaling pathway
15. DI MARCOTULLIO L, FERRETTI E, DE SMAELE E, AR-
GENTI B, MINCIONE C, ZAZZERONI F, GALLO R, MA-
SUELLI L, NAPOLITANO M, MARODER M, MODESTI A,
GIANGASPERO F, SCREPANTI I, ALESSE E, GULINO A 2004
REN(KCTD11) is a suppressor of Hedgehog signaling and is de-
leted in human medulloblastoma. PNAS 101(29): 10833–10838
16. STECCA B, MAS C, CLEMENT V, ZBINDEN M, CORREA R,
PIGUET V, BEERMAN F, RUIZ I ALTABA A 2007 Melanomas re-
quire HEDGEHOG-GLI signaling regulated by interactions be-
tween GLI1 and the RAS-MEK/AKT pathways. PNAS 104(14):
5895–5900
17. BAR-ELI M 2007 The HOG-GLI face of melanoma. Pigment Cell
Res 20(5): 341–342
18. VOØECHOVSKÝ I, UNDÉN A B, SANDSTEDT B, TOFT-
GARD R, STÄHLE-BÄCKDAHL M 1997 Trichoepitheliomas con-
tain somatic mutations in the overexpressed PTCH gene: support
for a gatekeeper mechanism in skin tumorigenesis. Cancer Res 57:
4677–4681
19. TOSTAR U, MALM C J, MEIS-KINDBLOM J M, KINDBLOM
L-G, TOFTGÅRD R, UNDÉN B 2006 Deregulation of the hedge-
hog signaling pathway: a possible role for the PTCH and SUFU
genes in human rhabdomyoma and rhabdomyosarcoma develop-
ment. J Pathol 208: 17–25
20. ZHAN S, HELMAN LJ 1998 Glimpsing the cause of rhabdomyo-
sarcoma. Nat Med 4(5): 559–560
21. QUALTHROUGH D, BUDA A, GAFFIELD W, WILLIAMS A C,
PARASKEVA C 2004 Hedgehog signalling in colorectal tumor cells:
induction of apoptosis with cyclopamine treatment. Int J Cancer 110:
831–837
22. KARHADKAR S S, BOVA G S, ABDALLAH N, DHARA S,
GARDNER D, MAITRA A, ISAACS J T, BERMAN D M, BEA-
CHY P A 2004 Hedgehog signaling in prostate regeneration, neo-
plasia and metastasis. Nature 431(7009): 707–712
23. WATKINS DN, BERMAN DM, BURKHOLDER SG, WANG B,
BEACHY PA, BAYLIN SB 2003 Hedgehog signaling within airway
epithelial progenitors and in small-cell lung cancer. Nature 422(20):
313–317
24. FUJITA E, KHOROKU Y, URASE K, TSUHAKARA T, MOMOI
MY, KUMAGAI H, TAKEMURA T, KUROKI T, MOMOI T 1997
Involvement of Sonic hedgehog in the cell growth of LK-2 cells, hu-
man lung squamous carcinoma cells. Biochem Biophys Res Comm
238: 658–664
25. THAYER S P, DI MAGLIANO M P, HEISER P W, NIELSEN C
M, ROBERTS D J, LAUWERS G Y, QI Y P, GYSIN S, FER-
NANDEZ-DEL CASTILLO C, YAJNIK V, ANTONIU B, MC-
MAHON M, WARSHAW A L, HEBROK M 2003 Hedgehog is an
early and late mediator of pancreatic cancer tumorigenesis. Nature
425(6960): 851–856
26. ABOULKASSIM T O, LARUE H, LEMIEUX P, ROUSSEAU F,
FRADET Y 2003 Alteration of the PATCHED locus in superficial
bladder cancer. Oncogene 22: 2969–2971
27. THIEVESSEN I, WOLTER M, PRIOR A, SEIFERT H-H, SC-
HULZ WA 2005 Hedgehog signaling in normal urothelial cells and
in urothelial carcinoma cell lines. J Cell Physiol 203: 372–377
28. VILA G, THEODOROPOULUOU M, STALLA J, TONN J C,
LOSA M, RENNER U, STALLA G K, PAEZ-PEREDA M 2005
Expression and function of Sonic hedgehog pathway components in
pituitary adenomas: evidence for a direct role in hormone secretion
and cell proliferation. J Clin Endocrin Metab 90(12): 6687–6694
29. KATANO M 2005 Hedgehog signaling pathway as a therapeutic
target in breast cancer. Cancer Lett 227(2): 99–104
30. CHEN X, HORIUCHI A, KIKUCHI N, OSADA R, YOSHIDA J,
SHIZAWA T, KONISHI I 2007 Hedgehog signal is activated in
ovarian carcinomas, correlating with cell proliferation: its inhibiton
leads to growth suppression and apoptosis. Cancer Sci 98(1): 68–76
31. LIAO X, SUI MKY, AU CWH, WONG ESY, CHAN HY, IP PCP,
NGAN HYS, CHEUNG ANY 2009 Aberrant activation of hedge-
hog signaling pathway in ovarian cancers: effect on prognosis, cell
invasion and differentiation. Carcinogenesis 30(1): 131–140
32. SENGUPTA A, BANERJEE D, CHANDRA S, BANERJI S K,
GHOSH R, ROY R, BANERJEE S 2007 Deregulation and cross
talk among Sonic hedgehog, Wnt, Hox and Notch signaling in
chronic myeloid leukemia progression. Leukemia 21: 949–955
33. CRETNIK M, MUSANI V, ORESKOVIC S, LEOVIC D, LE-
VANAT S 2007 The Patched gene is epigenetically regulated in ovar-
ian dermoids and fibromas, but not in basocellular carcinomas. Int J
Mol Med 19: 875–883
34. WOLF I, BOSE S, DESMOND J C, LIN B T, WILLIAMSON E
A, KARLAN B Y, KOEFFLER H P 2007 Unmasking of epigene-
tically silenced genes reveals DNA promoter methylation and re-
duced expression of PTCH in breast cancer. Breast Cancer Res Treat
105: 139–155
35. DU P, YE H R, GAO J, CHEN W, WANG Z C, JIANG H H, XU J,
ZHANG J W, ZHANG J C, CUI L 2009 Methylation of PTCH1a
gene in a subset of gastric cancers. World J Gastroenterol 15(30):
3799–3806
36. INGHAM P W, MCMAHON A P 2001 Hedgehog signaling in ani-
mal development: paradigms and principles. Genes Dev 15(23):
3059–87
37. TADA M, KANAI F, TANAKA Y, TATEISHI K, OHTA M, ASA-
OKA Y, SETO M, MUROYAMA R, FUKAI K, IMAZEKI F, KA-
WABE T, YOKOSUKA O, OMATA M 2008 Down-regulation of
Hedgehog-interacting protein through genetic and epigenetic alter-
ations in human hepatocellular carcinoma. Clin Cancer Res 14(12):
3768–3776
38. MARTIN S T, SATO N, DHARA S, CHANG R, HUSTNIX S R,
ABE T, MAITRA A, GOGGINS M 2005 Aberrant methylation of
the human Hedgehog Interacting Protein (HHIP) gene in pancre-
atic neoplasms. Cancer Biol Ther. 4(7): 728–33
39. SHAHI M H, LORENTE A, CASTRESANA J S 2008 Hedgehog
signalling in medulloblastoma, glioblastoma and neuroblastoma.
Oncol Rep 19(3): 681–8
40. WANG L H, CHOI Y L, HUA X Y, SHIN Y K, SONG Y J, YOUN
S J, YUN H Y, PARK S M, KIM W J, KIM H J, CHOI J S, KIM S H
2006 Increased expression of sonic hedgehog and altered methy-
lation of its promoter region in gastric cancer and its related lesions.
Mod Pathol 19(5): 675–83
Period biol, Vol 112, No 4, 2010. 423
Epigenetic regulation of the Hedgehog signaling pathway Diana Car et al.
